Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

effective as vancomycin in clinical cure, and was superior to vancomycin in global cure, defined as cure without a recurrence after 4 weeks of therapy. The advisory committee referred to the global cure outcome as 30-day resolution, which we believe is indicative of DIFICID's benefit in reducing recurrences," said Sherwood Gorbach, M.D., Optimer's Chief Medical Officer. "While the advisory committee vote was split on how best to describe the recurrence benefit, the committee members overwhelmingly recognized that DIFICID at 30 days was superior to vancomycin. We appreciated the committee's discussion and look forward to working with the FDA as it considers our DIFICID NDA."

The AIDAC based its decision in part on the review of clinical evidence from the two largest, comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. These multi-center, randomized, double-blind trials enrolled a total of 1,164 adults with confirmed CDI, who received either DIFICID (200 mg q12h) or vancomycin (125 mg q6h), the only FDA-approved product for the treatment of CDI. The objective of both studies was to show that a 10-day course of DIFICID was at least as efficacious (non-inferior) and safe as a 10-day course of vancomycin for the treatment of CDI. In both studies, DIFICID demonstrated a statistically significant reduction in the rate of recurrence compared with patients treated with vancomycin, reducing CDI recurrences by 47 percent, and was statistically superior to vancomycin in global cure rate (clinical cure without disease recurrence within four weeks). In addition, DIFICID met the primary endpoint of non-inferiority of clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication) compared to vancomycin.

DIFICID was safe and well tolerated in both studies, showing a similar incidence of treatment-related adverse events when compared to vancomycin.

Scheduled Conference Call


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Research and Development Trend Forecast of Pharmaceutical ... offering. Research and Development Trend Forecast ... , 2014-2018 mainly analyzes China,s ... status, supply & demand, competition landscape, and business performance ...
(Date:8/29/2014)... -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ... release its financial results for the fiscal 2014 fourth ... trading ends on Tuesday, September 9, 2014. ... p.m. U.S. EDT on Tuesday, September 9, 2014 (Wednesday, ... Company,s financial results, commercial partnerships, and future outlook.  The ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Md., April 11, 2012 Sunpeaks Ventures, Inc. (OTCBB: ... its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") ... an agreement with DS Healthcare Limited to assist in ... Under terms of the agreement, DS Healthcare will evaluate ...
... has used an electronic clinical system since its inception in ... original technology with an enterprise clinical and financial solution from ... start out as a completely electronic hospital. But we realize ... all of our needs," says Jeremy Lyman, CFO at the ...
Cached Medicine Technology:Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3
(Date:9/1/2014)... (PRWEB) September 01, 2014 Registration is now ... Warriors® 5K and 1-Mile Race to be held on Sunday, ... Plaza Court Yard at Harmon Meadow in Secaucus, New Jersey. ... Warriors®, a national nonprofit dedicated to restoring a sense of ... service members and our military families. , General registration is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... US FDA announced on August 28, that specific lots ... (Class I) as the device may reverse directions ... Synthes Craniomaxillofacial (CMF) Distraction System is an implant used ...
(Date:9/1/2014)... US (PRWEB) September 01, 2014 ... view into Heartbeat Experts’ perspectives on ... market. , Download the flash report to ... for any launching Diabetes product:, ... within an increasingly crowded market , ...
(Date:8/31/2014)... Just in time for Washington’s Indian Summer, ... Alaska Salmon, award winning chowder and legendary sourdough ... Lake location , Sunday, September 28, 2014 from 1 pm ... salmon BBQ culinary delights. Live music will add to the ... Rico and Mexico will be featured. “There is no ...
(Date:8/31/2014)... to celebrate the coming of autumn, Guangdong FODAY Automobile ... big promotion. Now, all the global clients can access cheap, ... are made with great materials. FODAY Automobile strives to offer ... of fact, it is providing big discounts on many of ... cheap cars can visit its website for more details. ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... SMITHFIELD, R.I., July 29 FGX International,(Nasdaq: FGXI ... sunglasses and costume jewelry, today announced financial results,for its ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071025/NETH104LOGO ), ... sales increased 14% to $71.6 million in the current ...
... WHITE PLAINS, N.Y., July 29 Four leaders,from the ... been elected to the national Board of Trustees of ... March of Dimes trustees, who serve as volunteers, represent ... and serve five-year,terms., The new trustees are:, ...
... cancer screening program in Norway and an approach to ... are equally sensitive for detecting cancer, researchers report in ... of the National Cancer Institute . But the recall ... Breast cancer screening in the United States is usually ...
... Income Per Share, SAN JOSE, Calif., July 29 ... leading provider of medical devices,for the minimally invasive treatment ... second quarter ended June 30, 2008., Net revenues ... $31.9,million compared with $17.2 million for the second quarter ...
... (Pink,Sheets: VSMD) announced today that Craig M. Walker, M.D., ... the number of directors from,four to five. Dr. Walker ... cardiologist, clinical investigator and thought leader., "Dr. Walker ... one of the,world,s leading experts in the care of ...
... literacy and,curbing HIV/AIDS is the centerpiece of the U.S. ... stabilize parts of,Haiti plagued by community unrest., The ... -- will,target public and private primary schools as well ... who manages a worldwide education and,health program for USAID., ...
Cached Medicine News:Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 2Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 3Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 4Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 5Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 6Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 7Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 8Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 9Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 10Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 11Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 12Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 13Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 14Health News:Four Named to March of Dimes Board of Trustees 2Health News:Four Named to March of Dimes Board of Trustees 3Health News:Four Named to March of Dimes Board of Trustees 4Health News:Four Named to March of Dimes Board of Trustees 5Health News:Four Named to March of Dimes Board of Trustees 6Health News:Four Named to March of Dimes Board of Trustees 7Health News:2 different breast cancer screening strategies are equally effective 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 4Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 5Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 6Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 7Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 8Health News:VASAMED(R) Appoints Craig M. Walker, MD to Board of Directors 2Health News:Three Rs and HIV/AIDS Mark New Haiti Literacy Plan 2
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Bipolar Atrial "J" Lead...
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: